NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free NRXP Stock Alerts $0.47 -0.06 (-11.28%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.42▼$0.5450-Day Range$0.29▼$0.7052-Week Range$0.22▼$1.20Volume2.53 million shsAverage Volume2.82 million shsMarket Capitalization$43.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NRx Pharmaceuticals alerts: Email Address NRx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.36 out of 5 starsMedical Sector904th out of 939 stocksPharmaceutical Preparations Industry428th out of 444 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for NRx Pharmaceuticals. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.02% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 36.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRXP. Previous Next 2.8 News and Social Media Coverage News SentimentNRx Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest19 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.MarketBeat Follows11 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.06% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.27% of the stock of NRx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($0.38) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNRx Pharmaceuticals has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyBombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.All the facts are here. About NRx Pharmaceuticals Stock (NASDAQ:NRXP)NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.Read More NRXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXP Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comNRx Pharmaceuticals Stock Set to Reverse Split on Tuesday, April 2nd (NASDAQ:NRXP)March 28, 2024 | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 28, 2024 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End HighlightsMarch 28, 2024 | prnewswire.comNRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingMarch 27, 2024 | msn.comNRx Pharmaceuticals Set to Unveil Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | finance.yahoo.comUPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024March 26, 2024 | americanbankingnews.comNRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on ThursdayMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 25, 2024 | finance.yahoo.comNRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKMarch 22, 2024 | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersMarch 21, 2024 | msn.comNRx Pharmaceuticals Forges Key Alliances to Bolster Ketamine Supply for Mental Health TreatmentMarch 21, 2024 | prnewswire.comNRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024March 21, 2024 | prnewswire.comNRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersMarch 18, 2024 | msn.comNRx Pharma to distribute HOPE Therapeutics stock, pay Ketamine royalty to holdersMarch 18, 2024 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx ShareholdersMarch 12, 2024 | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short SalesMarch 12, 2024 | msn.comNRx unveils plan to battle naked short selling in sharesMarch 12, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short SalesMarch 11, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)March 9, 2024 | finance.yahoo.comNRXP Apr 2024 2.000 callMarch 7, 2024 | finance.yahoo.comNRXP Apr 2024 1.000 callMarch 4, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionMarch 2, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy NRx Pharmaceuticals StockMarch 1, 2024 | msn.comNRx Pharmaceuticals announces $1M purchase agreementMarch 1, 2024 | markets.businessinsider.comNRx Pharmaceuticals Receives Approx. $1.0 Mln From Existing Investor - Quick FactsMarch 1, 2024 | finance.yahoo.comNRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per ShareSee More Headlines Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-699.48% Return on Assets-168.29% Debt Debt-to-Equity RatioN/A Current Ratio0.68 Quick Ratio0.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book4.29Miscellaneous Outstanding Shares92,426,000Free Float72,961,000Market Cap$43.62 million OptionableOptionable Beta0.99 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Jonathan C. Javitt M.D. (Age 67)M.P.H., Co-Founder, Chief Scientist Officer & Chairman Comp: $873.7kMr. Stephen H. Willard Esq. (Age 63)Acting Corporate Secretary, CEO & Director Comp: $501.19kDr. Riccardo Panicucci Ph.D. (Age 62)Chief Technology Officer Comp: $240kDr. Seth L. Van Voorhees Ph.D. (Age 63)Treasurer Comp: $399.96kMr. Richard Clavano Narido (Age 46)Interim CFO, Principal Financial Officer & Principal Accounting Officer Suzanne MessereInvestor RelationsDr. Philip T. Lavin Ph.D. (Age 77)Chief Methodologist Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistMr. Matthew Patrick Duffy (Age 61)Chief Business Officer More ExecutivesKey CompetitorsApollomicsNASDAQ:APLMEyenoviaNASDAQ:EYENRockwell MedicalNASDAQ:RMTILexaria BioscienceNASDAQ:LEXXOcuphire PharmaNASDAQ:OCUPView All CompetitorsInsiders & InstitutionsBridgeway Capital Management LLCSold 38,000 shares on 2/15/2024Ownership: 0.144%Citadel Advisors LLCSold 3,400 shares on 2/15/2024Ownership: 0.000%AdvisorShares Investments LLCBought 642,632 shares on 2/14/2024Ownership: 0.755%One Wealth Management Investment & Advisory Services LLCBought 140,402 shares on 1/25/2024Ownership: 0.165%Aaron GorovitzBought 35,000 shares on 8/30/2023Total: $11,200.00 ($0.32/share)View All Insider TransactionsView All Institutional Transactions NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed in 2024? NRx Pharmaceuticals' stock was trading at $0.46 at the beginning of the year. Since then, NRXP stock has increased by 2.6% and is now trading at $0.4719. View the best growth stocks for 2024 here. Are investors shorting NRx Pharmaceuticals? NRx Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,710,000 shares, an increase of 36.9% from the February 29th total of 2,710,000 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.0% of the company's stock are short sold. View NRx Pharmaceuticals' Short Interest. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals's stock reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has NRx Pharmaceuticals issued on next quarter's earnings? NRx Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of -0.400--0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -. Who are NRx Pharmaceuticals' major shareholders? NRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (0.75%), One Wealth Management Investment & Advisory Services LLC (0.16%), Bridgeway Capital Management LLC (0.14%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Aaron Gorovitz, Alessandra Daigneault, Chaim Hurvitz, Daniel C Javitt, Jonathan C Javitt, Patrick John Flynn, Robert Besthof, Stephen H Willard and Voorhees Seth Van. View institutional ownership trends. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.